Abstract 50P
Background
Papillary thyroid carcinoma (PTC) has a specific integrin expression signature that correlates with histopathology, specific driver gene mutations, and aggressiveness of the disease. α3β1 integrin is overexpressed, it is involved in PTC cell motility and invasion and is associated with an advanced disease and a worst outcome. Histopathology studies indicate that fibronectin 1 (FN1) and its integrin ligand αVβ3 are overexpressed in PTC. In normal thyroid cells, fibronectin (FN) stimulates DNA synthesis, proliferation and survival through αVβ3 binding.
Methods
The mRNA expression of integrins and FN1 genes in normal thyroid tissues and PTC were assessed in the TCGA database. -The level of FN and αVβ3 in was assessed by immunofluorescence in PTC cell lines (BCPAP, K1) and in a normal thyroid cell line (Nthy-ori3-1). -The release and deposition of FN were estimated by enzyme-linked immunoassay. - The proliferation was measured by MTT assay. -The silencing of gene FN1 in the K1 cell line was performed with KN2.0, non-homology mediated CRISPR knockout kit (ORIGENE®).
Results
Analysis of the TCGA database on 402 PTC and 82 healthy tissues demonstrates that FN1 mRNA is 60 times more expressed in PTC than in healthy tissue and that the ITGAV and ITGB1 subunits are more expressed. The increase in FN1 and ITGAV mRNA expression is associated with metastatic lymph nodes, more advanced staging, extrathyroidal extension, and higher risk. PTC cells show higher expression of integrin αVβ3, the main receptor of FN1 and at the same time a high production of fibronectin. The gene FN1 was silenced in K1 cell line (K1FN1-/-). Both K1 and K1FN1-/- seeded in collagen coated plates attached and survived in the absence of serum. While K1 proliferated under these culture conditions, proliferation was almost absent in K1FN1-/- and was rescued by soluble FN.
Conclusions
Papillary thyroid carcinoma cells express high amounts of αVβ3 integrin and produce more fibronectin. - Fibronectin/ αVβ3 interaction could be a mechanism of disease progression in PTC. - Fibronectin can be a powerful prognostic indicator and a site of pharmacological intervention.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
University of Salerno.
Funding
Department of Medicine, Surgery and Dentistry, University of Salerno.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
48P - Early cancer detection from liquid biopsy using cell-free RNA
Presenter: Joao Curado
Session: Cocktail & Poster Display session
Resources:
Abstract
49P - Numb serves as a prognostic biomarker and promotes lung adenocarcinoma brain metastasis
Presenter: Yanyan Zhao
Session: Cocktail & Poster Display session
Resources:
Abstract
51P - Correlation of IL-6 and c-reactive protein levels with the stage, differentiation and types of colorectal cancer
Presenter: MOHAMED MAHBOOB ALI
Session: Cocktail & Poster Display session
Resources:
Abstract
52P - RAS mutation status and mutation type as potential predictive biomarkers for thrombosis in metastatic colorectal cancer: A tertiary center 12-year cohort analysis
Presenter: José Leão Mendes
Session: Cocktail & Poster Display session
Resources:
Abstract
53P - Assessment of cancer testis antigen 45 for diagnostic and prognostic applications in ovarian cancer
Presenter: Harshita Dubey
Session: Cocktail & Poster Display session
Resources:
Abstract
54P - Integrative omics workflow identifies credible druggable targets in high-grade serous cancer
Presenter: Taru Muranen
Session: Cocktail & Poster Display session
Resources:
Abstract
55P - Impact of IHC/PCR discordance on immunotherapy (ICI) response in colorectal cancer (CRC) patients and prospects of liquid biopsy (LB) to replace conventional methods: Survival analysis of BLOOMSI trial
Presenter: Alexandra Lebedeva
Session: Cocktail & Poster Display session
Resources:
Abstract
57P - Response of gastric adenocarcinoma to neoadjuvant chemotherapy with respect to the presence or absence of HER2 overexpression: A prospective observational study
Presenter: Pratap Deb
Session: Cocktail & Poster Display session
Resources:
Abstract
58P - NSCLC genomic complexity: Insights from comprehensive molecular profiling in the era of precision medicine
Presenter: Preeti Paliwal
Session: Cocktail & Poster Display session
Resources:
Abstract
59P - Identifying blood-based proteomic mediators of cancer-associated cachexia in non-small cell lung cancer in the TRACERx study
Presenter: Rachel Scott
Session: Cocktail & Poster Display session
Resources:
Abstract